Loading cancer entity…
Loading cancer entity…
Clinical trials
972 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (145)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05123001 | Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events | completed | — | 11 | Stanford UniversityOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT01771107 | Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 41 | National Cancer Institute (NCI)NIH | 2 | Aug 15, 2025 | clinicaltrials |
| NCT03159897 | FIL Study on ABVD DD-DI as Upfront Therapy in HL. | completed | Phase 3 | 500 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT03739619 | Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 3 | Emory UniversityOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT03331341 | Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 50 | University of WashingtonOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT04473911 | Haplo Peripheral Blood Sct In GVHD Prevention | completed | Phase 1 | 25 | Zachariah Michael DeFilippOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT02722668 | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep | completed | Phase 2 | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT05008224 | Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)(KEYNOTE-C11) | completed | Phase 2 | 146 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Jun 6, 2025 | clinicaltrials |
| NCT01350245 | Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor | completed | Phase 2 | 28 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT05053100 | Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study | completed | — | 100 | Mayo ClinicOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT02566304 | Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 35 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT03755414 | Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation | completed | Phase 1 | 55 | Washington University School of MedicineOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT03004833 | Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma(NIVAHL) | completed | Phase 2 | 110 | University of CologneOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT03894618 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 49 | Shattuck Labs, Inc.INDUSTRY | 4 | Apr 2, 2025 | clinicaltrials |
| NCT02744612 | Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 2 | 39 | City of Hope Medical CenterOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT01476839 | Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06857500 | Brentuximab Vedotin with Adriamycin, Vinblastine and Dacarbazine for Patients Aged 18-59 Years with Untreated Advanced-stage Classical Hodgkin Lymphoma: a Real-life Experience(FED_RealBV) | completed | — | 200 | Federico II UniversityOTHER | 1 | Mar 4, 2025 | clinicaltrials |
| NCT02396134 | Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | completed | Phase 2 | 61 | City of Hope Medical CenterOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT01701986 | Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 64 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT05131815 | The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors | completed | N/A | 8 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT02824029 | Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | completed | Phase 2 | 28 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT02927769 | A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment(CheckMate 744) | completed | Phase 2 | 72 | Bristol-Myers SquibbINDUSTRY | 11 | Feb 10, 2025 | clinicaltrials |
| NCT06814860 | Microenvironmental Trial of Classical Hodgkin Lymphoma in Adolescents(LH2004ME) | completed | — | 36 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT03209973 | A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma | completed | Phase 2 | 70 | BeiGeneINDUSTRY | 1 | Feb 5, 2025 | clinicaltrials |
| NCT03615664 | The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD(BURGUND) | completed | Phase 2 | 115 | Polish Lymphoma Research GroupNETWORK | 1 | Jan 16, 2025 | clinicaltrials |
| NCT05066555 | Circulating Tumor DNA Genotyping for Biological Monitoring of Patients Treated in the FIL-Rouge Clinical Trial(FIL-RougeBIO) | completed | — | 100 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT01956084 | Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma(ALCI2) | completed | Phase 1 | 10 | Catherine BollardOTHER | 1 | Dec 19, 2024 | clinicaltrials |
| NCT06093334 | Imaging of Chemotherapy-induced Morphological and Functional Lung Changes in Childhood ALL and HD(MinimALL) | completed | N/A | 27 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | Dec 17, 2024 | clinicaltrials |
| NCT03524235 | Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL | completed | Phase 1 | 20 | Noah MerinOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT05260203 | MargheRITA (Remote Intelligence for Therapeutic Adherence)(MargheRITA) | completed | N/A | 124 | Advice Pharma Group srlINDUSTRY | 1 | Nov 6, 2024 | clinicaltrials |
| NCT04986189 | Lung Screening in People Cured of Hodgkin Lymphoma | completed | N/A | 102 | The Christie NHS Foundation TrustOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT02453594 | Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087) | completed | Phase 2 | 211 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Oct 29, 2024 | clinicaltrials |
| NCT00285259 | Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) | completed | Phase 2 | 112 | Astellas Pharma IncINDUSTRY | 1 | Oct 21, 2024 | clinicaltrials |
| NCT04998331 | A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin(BELIEVE) | completed | — | 51 | TakedaINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT01793233 | Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas | completed | — | 203 | Children's Oncology GroupNETWORK | 2 | Aug 26, 2024 | clinicaltrials |
| NCT02191930 | Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma(BVB) | completed | Phase 2 | 70 | University of CologneOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT06564259 | Relationship Between Serum β2-Microglobulin and Infiltration of CD8+ in the Tumor Tissue of Hodgkin's Lymphoma Patients | completed | — | 144 | Latakia UniversityOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT02595866 | Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | completed | Phase 1 | 58 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2024 | clinicaltrials |
| NCT02576496 | Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies | completed | Phase 1 | 106 | Mundipharma Research LimitedINDUSTRY | 7 | Jul 25, 2024 | clinicaltrials |
| NCT03942263 | A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian Federation(KLIO) | completed | — | 2,000 | TakedaINDUSTRY | 1 | Jul 15, 2024 | clinicaltrials |
| NCT01716806 | A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) | completed | Phase 2 | 131 | Seagen Inc.INDUSTRY | 2 | Jun 11, 2024 | clinicaltrials |
| NCT01597219 | Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers(UK-Haplo) | completed | Phase 2 | 77 | University College, LondonOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT02981914 | Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation | completed | Early Phase 1 | 12 | University of ChicagoOTHER | 1 | Apr 22, 2024 | clinicaltrials |
| NCT04666025 | SARS-CoV-2 Donor-Recipient Immunity Transfer | completed | — | 26 | City of Hope Medical CenterOTHER | 1 | Apr 8, 2024 | clinicaltrials |
| NCT03722147 | A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 94 | AkesoINDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT01588015 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant | completed | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT04052997 | Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 2 | 117 | ADC Therapeutics S.A.INDUSTRY | 11 | Mar 28, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Aug 29, 2025source: clinicaltrials